Research
Hormonal
Targeting specific inflammatory pathways (e.g., IL-1, TNFα, IL-6) with pharmacological antagonists can improve insulin sensitivity and glycemic control in patients with obesity and related inflammatory conditions.
In clinical settings, reducing inflammation through targeted medications can help manage blood sugar and insulin resistance in obese patients, especially those with co-existing inflammatory diseases. This supports the broader goal of reducing metabolic risk.
GoodSupportsHIGH confidence
Pharmaceuticals targeting immunological modulators have been shown to improve insulin sensitivity in humans as well. For example, in patients afflicted with both rheumatoid arthritis and diabetes, IL-1R antagonist has demonstrated the capacity to enhance insulin sensitivity... Clinical trials have unveiled the potential of TNFα antagonists in inhibiting the development of type 2 diabetes.
Why this rating
Cites clinical trials and patient data, though specific dosing protocols are not the focus of this review.
Source
Relevance and consequence of chronic inflammation for obesity development
Lisa Rück et al. · Molecular and Cellular Pediatrics · 2023
DOI 10.1186/s40348-023-00170-6
narrative_reviewCited 25×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Chronic inflammation in adipose tissue, driven by macrophage infiltration (M1 phenotype) and pro-inflammatory cytokine release (TNFα, IL-6), directly causes insulin resistance and contributes to the development of obesity and metabolic syndrome.Good
- Hypothalamic inflammation, characterized by microglial activation and increased SOCS3 expression, leads to leptin and insulin resistance in the central nervous system, promoting orexigenic signaling and weight gain.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →